ISB News

Nature News: ‘Medicine Gets Up Close and Personal’ – Dr. Lee Hood’s Vision for Wellness

Infographic showing types of data

"Even in its pilot phase, the project is unusually thorough. The ISB will sequence the whole genome of each participant at the outset. And in later phases, Hood says, the study team will also examine epigenetics: methylation and other modifications to DNA that can reflect environmental exposures. But that is just the tip of the data-collection iceberg." — From 'Medicine Gets Up Close and Personal' in Nature

The journal Nature pubished a news article today (online Feb. 11, 2014/print Feb. 12, 2014) about Dr. Lee Hood's vision for the 100K Wellness Project. The project will launch in March first with a 100-person study that eventually will scale to 100,000 individuals. Read the Nature article, written by W. Wayt Gibbs, at this link.

To learn more, watch a video of Dr. Lee Hood talk about his vision for the 100K Wellness Project:

Recent Articles

  • Co-corresponding author and ISB President Dr. Jim Heath and co-lead author Dr. Yapeng Su.

    For Cancer Cells, There Is More Than One Path to Drug Resistance

    In findings published in the journal Nature Communications, researchers show that cancer cells can take more than one path to reach a drug-resistant cell state. These findings could have promising implications for the future of cancer care.

  • ISB researchers

    Unveiling the Guerrilla Warfare Tactics of Mycobacterium Tuberculosis

    ISB researchers have unveiled new insights on how Mycobacterium tuberculosis, the pathogen that causes tuberculosis, enters and exits a dormant state in human hosts. About a quarter of the world’s population has latent TB, so these important findings will enable and accelerate the discovery of more effective TB drugs.

  • Merck and ISB Collaborate to Understand and Treat SARS-CoV-2 Infection

    Merck is collaborating with ISB and its partners to analyze blood samples and nasal swabs from Swedish Medical Center patients with SARS-CoV-2. Blood samples will be examined using proteomic, metabolomic, transcriptomics and genetic techniques to evaluate the impact of infection on different organs, and to identify potential biomarkers to predict the risk of severe disease.